AbbVie said the study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a starting dose of 15 mg daily versus dupilumab at its labeled dose. Also Read: Is Your Botox ...

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

In clinical trials, new medications such as upadacitinib and dupilumab have shown promising results for patients with moderate to severe atopic dermatitis. Upadacitinib, an oral Janus kinase ...

Self-reported manifestations of topical steroid withdrawal in atopic dermatitis include erythema, desquamation, dryness, and oozing.

The drug is also being studied in other immune-mediated diseases – phase 3 trials of upadacitinib in atopic dermatitis, psoriatic arthritis, Crohn's disease, and ulcerative colitis are ongoing ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Members of an international team of experts in atopic dermatitis (AD) have recommended oral JAK inhibitors for patients ...

EADV 2024 Nemolizumab Reassures in Long-Term Atopic Dermatitis Study ... events in patients treated with upadacitinib and abrocitinib for atopic dermatitis. Medscape Medical News, October 18 ...

Eli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which ... Sciences’ filgotinib and AbbVie’s upadacitinib. These are being developed ...